Business Context and Reporting Period
Filing: Form 10-Q for the quarter ended March 31, 2017. The filing identifies the registrant as PowerVerde, Inc.; the request metadata references 374Water Inc., so the issuer identity should be verified.
The company is developing and commercializing clean-energy electric power generation systems, but planned principal operations had not commenced. All reported revenue came from legacy biotech intellectual-property royalty arrangements, unrelated to the planned clean-energy business.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2017 | Three Months Ended March 31, 2016 |
|---|---|---|
| Royalty revenue | $171,251 | $140,652 |
| Operating expenses | $106,100 | $144,036 |
| Income (loss) from operations | $65,151 | $(3,384) |
| Interest expense | $(9,945) | $(14,684) |
| Net income (loss) | $55,206 | $(18,068) |
| Net income (loss) per share | $0.00 | $(0.00) |
| Cash provided by operating activities | $28,674 | $97,362 |
| Cash and cash equivalents at period end | $8,460 | $54,416 |
Approximate 2017 operating margin was 38.0% and net margin was 32.2%, compared with negative margins in the 2016 quarter. The filing does not provide a separate product gross margin because revenue consisted entirely of royalties.
- Total assets were $363,574 at March 31, 2017.
- Total liabilities were $449,268, including $400,000 of notes payable to related parties.
- Stockholders’ deficiency was $(85,694).
- Working capital deficit was $207,803, improved from $272,120 at December 31, 2016.
- Cash flow from financing activities was negative $25,000, reflecting a payment on related-party notes.
- Accounts receivable were $171,251 and were considered fully collectible.
Material Changes Versus the Prior Comparable Period
- Royalty revenue increased $30,599, or approximately 21.7%.
- Research and development expense decreased $10,068, or 17.4%, because the company was testing rather than building new generator systems.
- General and administrative expense decreased $27,868, or 32.3%, primarily because of lower accounting and legal expenses.
- The company moved from a $18,068 net loss to $55,206 of net income.
- Operating cash flow declined $68,688 despite the improved earnings result, mainly because the prior-year period benefited from favorable working-capital changes.
- Cash decreased substantially from the prior-year quarter-end, falling from $54,416 to $8,460.
Guidance, Outlook, Risks, and Unusual Items
- Management expects 2017 biotech intellectual-property royalty revenue to approximate 2016 levels, but provides no assurance that this level will be achieved.
- The license agreement generating all company revenue since 2012 is scheduled to terminate in March 2018 when the underlying patents expire.
- The $400,000 secured related-party notes, bearing 10% interest, were extended to September 30, 2017. The company intends to apply most second- and third-quarter royalty receipts toward principal and interest. It paid $100,000 toward principal in April 2017.
- Management stated that it needs to promptly raise substantial additional capital and that failure to obtain funding could force the company to cease operations.
- The financial statements include a going-concern uncertainty arising from recurring operating losses, historical negative operating cash flow, negative working capital, and uncertainty regarding additional financing.
- Management intends to reduce salary and consulting expenses until the related-party notes are repaid and is seeking additional revenue through part-time skilled manufacturing services.
- The company has a ten-year Helidyne license, prepaid $38,750 toward two expanders, and future royalty obligations that begin upon commercialization or three years from the agreement date, subject to minimum annual royalties.
- Outstanding potentially dilutive securities included warrants exercisable for 4,275,000 shares and options for 5,750,500 shares; these were excluded from diluted earnings per share because their effect was anti-dilutive or immaterial.
- No legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded that disclosure controls and internal control over financial reporting were effective.
Investor Verification Points
- Verify whether this filing belongs to 374Water Inc. or PowerVerde, Inc., as the filing text names PowerVerde.
- Confirm the collectibility and timing of the $171,251 royalty receivable and the expected duration of royalty receipts before the March 2018 license termination.
- Verify repayment terms, collateral, accrued interest, and the April 2017 $100,000 payment on the related-party notes.
- Assess whether the company can obtain sufficient debt or equity financing given its $8,460 cash balance, working capital deficit, and going-concern disclosure.
- Evaluate the feasibility and funding requirements of commercializing the clean-energy systems, since planned principal operations had not commenced.
- Reconcile the balance sheet totals: the filing reports December 31, 2016 total assets of $363,173 but total liabilities and stockholders’ deficiency of $361,173, an apparent $2,000 internal discrepancy.